GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Archived. This submission is more than a year old. Votes and new comments are closed, and some of the advice in it may have been superseded — check the community wiki for the current version.
263
c/orforglipron·posted 1 year ago by u/hedda_ekstrom

[Lab] CPC orfo — Janoshik came back 98.2% against a claimed 97.5%

Question Receipts ×5

Posting this because the title is the whole finding — CPC orfo — Janoshik came back 98.2% against a claimed 97.5% — and a number without its method is a rumour.

The relevant figures are 98.2% and 97.5%, and they come from the same log I have kept the whole time.

It is a non-peptide small-molecule agonist at the GLP-1 receptor. That is a substantial medicinal chemistry achievement: getting a small molecule to activate a receptor evolved for a peptide ligand.

Because it is not a peptide, it is not subject to the same degradation pathways, does not require the absorption enhancers used for oral peptides, and can be formulated as a conventional tablet.

Please do not ask me what dose you should be on. I genuinely do not know and neither does anyone else here.

370 up / 107 down78% upvoted10 commentsid 1v8ifs18 Sep 2024
Supplier named in this thread
The source page carries the verification log and every independent test a member has paid for. The storefront link is marked nofollow and sponsored; nobody here is paid for it.

10 comments

4 in this archive, depth 2

best — the order this archive was captured in

u/sofia_petrescu26 points·1 year ago

Milligram comparisons across molecule classes are meaningless. Potency is a property of the molecule at its receptor, not of the number on the label.

replysharereportpermalink
u/santiago_villalobos11 points·1 year ago

Disagree. You are comparing doses across a small molecule and a peptide, which is not a comparison of anything.

replysharereportpermalink
u/lina_bruun15 points·1 year ago

phase 3 is where the comparison becomes fair

replysharereportpermalink
u/quiet_moderatormod24 points·1 year ago

Compared milligram figures across two completely different molecule classes in a comment. Deserved the correction.

replysharereportpermalink
About c/orforglipron

The small-molecule oral: why a non-peptide agonist escapes the absorption problems of oral semaglutide, what the ATTAIN and ACHIEVE readouts showed, and what a pill with no refrigeration requirement would do to the entire supply conversation this site is built around.

21kmembers
62submissions
Feb 2024created
submissions / month, last year
Sponsored

Sigma-Aldrich Standards

Certified reference materials for peptide identity and purity work.

sigmaaldrich.com
c/orforglipron rules
  1. Small molecule, not a peptide. Purity discussion here is a different problem.
  2. Cite ATTAIN/ACHIEVE arms specifically when quoting numbers.
  3. Availability speculation must be flaired Speculation.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Moderators
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.